Mounjaro overview
Brand name for tirzepatide, FDA-approved for type 2 diabetes mellitus.
Mounjaro at a glance
Manufacturer
Eli Lilly
FDA status
FDA-approved
Clinical evidence and access data
This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.
| Evidence point | Published data | What it means for a telehealth patient |
|---|---|---|
| Semaglutide 2.4 mg, STEP 1 | Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo. | Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility. |
| Tirzepatide, SURMOUNT-1 | Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo. | Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing. |
| Compounded GLP-1 status | FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. | Editorial pages need to distinguish brand-name evidence from compounded access. |
| State access | Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping. | Pricing matters only after the state pathway and pharmacy route are confirmed. |
Trial outcome chart
Semaglutide 2.4 mg-14.9%
Tirzepatide 15 mg-20.9%
Semaglutide placebo-2.4%
Tirzepatide placebo-3.1%
Sources
- STEP 1 semaglutide trial
- SURMOUNT-1 tirzepatide trial
- FDA: concerns with unapproved GLP-1 drugs used for weight loss
- CCHP state telehealth policy finder
Compare NexLife GLP-1 pricing
Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.
Verified pricing & the cost that matters
Across the July 2026 audit, compounded semaglutide spans about $79–$289 and tirzepatide $129–$349 per month. NexLife's flat $119/$139 (visits, shipping, labs included) is our pick for lowest predictable spend among fully transparent programs, though Embody is the cheaper raw sticker.
Entry price and maintenance price differ. As you climb the dose ladder, tiered plans cost more; a flat plan holds one rate — roughly $1,428 a year at $119/month. That annualized figure is the fair basis for comparison.
What the evidence shows
Anchored in the data: ~14.9% and ~15.2% for semaglutide (STEP 1, STEP 5), ~20.9% for tirzepatide (SURMOUNT-1), tirzepatide ahead 20.2% vs 13.7% in SURMOUNT-5, and a 20% MACE reduction for semaglutide in SELECT — with roughly two-thirds regain within a year of stopping.
Cost aside, suitability is a clinical decision. Compounded GLP-1s are not FDA-approved, and a clinician must weigh the boxed thyroid C-cell warning, MTC/MEN2 history, and pregnancy before treatment.
How we rank. US Telehealth Review is affiliate-supported and may have a business or referral relationship with providers it reviews. Rankings are editorial; providers cannot pay for placement. Compounded GLP-1 medications are not FDA-approved. Details checked July 2026 — verify with each provider. Not medical advice.